UBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains "Buy" Rating

Stock News

Yesterday

UBS has issued a research report noting that Hansoh Pharma's (03692) B7-H3-targeted antibody-drug conjugate (ADC), Ris-Rez, demonstrated positive results in a Phase 3 study for treating relapsed small cell lung cancer (SCLC). The treatment showcased improved survival rates and tumor control, along with fewer treatment-related adverse events, presenting an encouraging efficacy profile when compared against the control group.

The firm has assigned a "Buy" rating to Hansoh Pharma with a target price of HK$50.8. UBS highlighted that the New Drug Application (NDA) for Ris-Rez in SCLC has been accepted by the NMPA and granted priority review status. The bank anticipates that this study will bolster the company's commercialization efforts in China and further solidify the clinical validation of its ADC platform.

However, UBS also pointed out that with intensifying competition in the B7-H3 ADC space, product differentiation remains an area that needs to be established.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/news/1122176478"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122176478\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122176478?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 10:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122176478","market":"nz","top_or_hot":-1,"title":"UBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains \"Buy\" Rating","media":"Stock News","content":"<p>UBS has issued a research report noting that Hansoh Pharma's (03692) B7-H3-targeted antibody-drug conjugate (ADC), Ris-Rez, demonstrated positive results in a Phase 3 study for treating relapsed small cell lung cancer (SCLC). The treatment showcased improved survival rates and tumor control, along with fewer treatment-related adverse events, presenting an encouraging efficacy profile when compared against the control group.<br><br>The firm has assigned a \"Buy\" rating to Hansoh Pharma with a target price of HK$50.8. UBS highlighted that the New Drug Application (NDA) for Ris-Rez in SCLC has been accepted by the NMPA and granted priority review status. The bank anticipates that this study will bolster the company's commercialization efforts in China and further solidify the clinical validation of its ADC platform.<br><br>However, UBS also pointed out that with intensifying competition in the B7-H3 ADC space, product differentiation remains an area that needs to be established.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains \"Buy\" Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUBS Highlights Encouraging Phase 3 Data for Hansoh Pharma's Ris-Rez in Relapsed Small Cell Lung Cancer, Maintains \"Buy\" Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-15 10:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>UBS has issued a research report noting that Hansoh Pharma's (03692) B7-H3-targeted antibody-drug conjugate (ADC), Ris-Rez, demonstrated positive results in a Phase 3 study for treating relapsed small cell lung cancer (SCLC). The treatment showcased improved survival rates and tumor control, along with fewer treatment-related adverse events, presenting an encouraging efficacy profile when compared against the control group.<br><br>The firm has assigned a \"Buy\" rating to Hansoh Pharma with a target price of HK$50.8. UBS highlighted that the New Drug Application (NDA) for Ris-Rez in SCLC has been accepted by the NMPA and granted priority review status. The bank anticipates that this study will bolster the company's commercialization efforts in China and further solidify the clinical validation of its ADC platform.<br><br>However, UBS also pointed out that with intensifying competition in the B7-H3 ADC space, product differentiation remains an area that needs to be established.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"","article_id":"1122176478","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122176478","pubTimestamp":1789440859,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"UBS has issued a research report noting that Hansoh Pharma's (03692) B7-H3-targeted antibody-drug conjugate (ADC), Ris-Rez, demonstrated positive results in a Phase 3 study for treating relapsed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","03692":"翰森制药","BK1589":"北水核心资产","BK1191":"制药"},"translate_title":"瑞银强调豪森制药 Ris-Rez 治疗复发性小细胞肺癌的令人鼓舞的 3 期数据，维持“买入”评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"UBS has issued a research report noting that Hansoh Pharma's (03692) B7-H3-targeted antibody-drug conjugate (ADC), Ris-Rez, demonstrated positive results in a Phase 3 study for treating relapsed small cell lung cancer (SCLC). The treatment showcased improved survival rates and tumor control, along with fewer treatment-related adverse events, presenting an encouraging efficacy profile when compared against the control group.The firm has assigned a \"Buy\" rating to Hansoh Pharma with a target price of HK$50.8. UBS highlighted that the New Drug Application (NDA) for Ris-Rez in SCLC has been accepted by the NMPA and granted priority review status. The bank anticipates that this study will bolster the company's commercialization efforts in China and further solidify the clinical validation of its ADC platform.However, UBS also pointed out that with intensifying competition in the B7-H3 ADC space, product differentiation remains an area that needs to be established.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}